HemeHub
@hemehub.bsky.social
34 followers 61 following 95 posts
HemeHub (formerly BMFCases) | Supporting hematology by enhancing care, driving innovation, and advancing research & treatment strategies. https://www.hemehub.org
Posts Media Videos Starter Packs
hemehub.bsky.social
Why might anemia persist in a patient treated with Lyfgenia despite elimination of VOCs?

See the answer and explanation on the next slide!

#Lyfgenia #LentiGlobin #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy
hemehub.bsky.social
Today’s question explores how vector copy number relates to treatment outcomes in patients receiving Lyfgenia.

Check out the answer on the next slide along with its explanation!

#Lyfgenia #GeneTherapy #SickleCellDisease #Hematology #RareDiseases #BloodDisorders #MedicalEducation
hemehub.bsky.social
Facts about #SickleCellDisease and #GeneTherapy

Study Focus: #LentiGlobin

The HGB-206 clinical trial refined the treatment process, including transfusion regimens, busulfan conditioning, and manufacturing methods, leading to improved and consistent outcomes for patients with sickle cell disease.
hemehub.bsky.social
Today’s question highlights the clinical effects of Lyfgenia™ in a patient with SCD.

Check out the answer on the next slide along with its explanation!

@ascaa.bsky.social @sicklecell101.bsky.social @sicklecelluk.bsky.social @asgct.bsky.social #SickleCellDisease #Hematology #BloodDisorders
hemehub.bsky.social
An overview of Lyfgenia and the antisickling hemoglobin HbAT87Q, highlighting the mechanism by which autologous stem cells are engineered to restore functional red blood cells.

@ascaa.bsky.social @sicklecell101.bsky.social @sicklecelluk.bsky.social #SickleCellDisease #Hematology #CellTherapy
hemehub.bsky.social
This Month on HemeHub: SCD and Gene Therapy

Join us as we explore advances in the treatment of #sicklecelldisease through #genetherapy, featuring pivotal trials of Lyfgenia and Casgevy.

Stay tuned for our upcoming session featuring Dr. John Tisdale, Senior Investigator at the NHLBI.
hemehub.bsky.social
Today's second question is about the diagnostic approach to JAK2-unmutated #erythrocytosis and the appropriate next step in evaluation.

The third question focuses on the mechanism by which HFE mutations contribute to #erythrocytosis.

Check out the answers to both questions on the next slides!
hemehub.bsky.social
Today’s first question highlights a key distinguishing feature of TEMPI syndrome in clinical practice.

#JAK2NegativeErythrocytosis #NonPVErythrocytosis #Erythrocytosis #Hematology #MyeloproliferativeDisorders #SecondaryErythrocytosis #EPO #Hypoxia #GermlineMutations #ClinicalHematology
hemehub.bsky.social
Facts about JAK2 unmutated erythrocytosis:

Genetic variants in Epo signaling, oxygen affinity, and iron metabolism can all contribute to inherited erythrocytosis.

@bsochaem.bsky.social @ash.edu.hematology.org @vjhemonc.bsky.social @rarediseasectn.bsky.social #Erythrocytosis #Hematology
hemehub.bsky.social
Today’s question is about the complications of erythrocytosis in congenital heart disease and their underlying associations.

#JAK2NegativeErythrocytosis #Erythrocytosis #Hematology @bsochaem.bsky.social @vjhemonc.bsky.social @ash.hematology.org @ash.edu.hematology.org @cuhemeonc.bsky.social
hemehub.bsky.social
Facts about JAK2 unmutated erythrocytosis:

The HIF-PHD-VHL pathway, driven by HIF2A, links oxygen and iron sensing to Epo production and hypoxia-induced erythrocytosis.

@vjhemonc.bsky.social @ash.hematology.org @ash.edu.hematology.org @bsochaem.bsky.social #Erythrocytosis #Hematology
hemehub.bsky.social
Missed our session with Dr. Naseema Gangat on JAK2 Unmutated Erythrocytosis? The full recording is now available on our YouTube channel!

➡️Watch the full session: www.youtube.com/watch?si=Qeq...

@bsochaem.bsky.social @vjhemonc.bsky.social @cuhemeonc.bsky.social @bsochaem.bsky.social #Hematology
hemehub.bsky.social
Today’s question is about evaluating causes of erythrocytosis in a JAK2-negative patient with menorrhagia.

Check out the answer on the next slide along with its explanation!

@ash.edu.hematology.org @stanfordmedicine.bsky.social @bcmhouston.bsky.social @medicine.stitches.today @bsochaem.bsky.social
hemehub.bsky.social
Facts about JAK2 unmutated erythrocytosis:

Post-renal transplant erythrocytosis declines with ACEi/ARBs; management is monitoring and CV risk control, not routine phlebotomy or JAK2 inhibitors.

#JAK2NegativeErythrocytosis #Erythrocytosis #Hematology #MyeloproliferativeDisorders
hemehub.bsky.social
Today’s question is about predisposing factors for erythrocytosis.

Check out the answer on the next slide along with its explanation!

@ash.edu.hematology.org @stanfordmedicine.bsky.social @bcmhouston.bsky.social @yaleschoolofmed.bsky.social @medicine.stitches.today @dukemedschool.bsky.social
hemehub.bsky.social
Facts about JAK2-unmutated erythrocytosis:

How SGLT-2 inhibitors and testosterone therapy can raise hemoglobin/hematocrit and what current guidelines recommend for management.

#Hematology @ash.edu.hematology.org @rarediseasectn.bsky.social @bsochaem.bsky.social
@vjhemonc.bsky.social
hemehub.bsky.social
Facts about JAK2 unmutated erythrocytosis:

In Chuvash polycythemia and high oxygen affinity hemoglobin, thrombosis risk is linked to age and cardiovascular factors—not hematocrit—and phlebotomy or hydroxyurea are generally not beneficial.

#Erythrocytosis #Hematology #MyeloproliferativeDisorders
hemehub.bsky.social
Facts about JAK2-unmutated erythrocytosis:

Phlebotomy isn’t recommended for asymptomatic patients, may be harmful in physiologic cases, and can cause its own side effects.

@ash.edu.hematology.org @vjhemonc.bsky.social @rarediseasectn.bsky.social @bsochaem.bsky.social @ash.hematology.org
hemehub.bsky.social
Today’s question!

Check out the answer on the next slide along with its explanation.

#Hematology #Medicine #Erythrocytosis #MyeloproliferativeDisorders @ash.edu.hematology.org @bsochaem.bsky.social @rarediseasectn.bsky.social @rarediseasesint.bsky.social @ash.hematology.org @vjhemonc.bsky.social
hemehub.bsky.social
Today’s question!

Check out the answer on the next slide along with its explanation.

@ash.edu.hematology.org @rarediseasectn.bsky.social @rarediseasesint.bsky.social @bsochaem.bsky.social @vjhemonc.bsky.social #Erythrocytosis #Hematology #MyeloproliferativeDisorders #SecondaryErythrocytosis #EPO
hemehub.bsky.social
Facts about JAK2 Unmutated Erythrocytosis:

Treatment isn’t based on strong evidence, and phlebotomy is mainly for symptom control.

@ash.edu.hematology.org @bsochaem.bsky.social @vjhemonc.bsky.social @rarediseasectn.bsky.social @rarediseasesint.bsky.social
hemehub.bsky.social
Today’s question!

Check out the answer on the next slide along with its explanation.

#JAK2NegativeErythrocytosis #NonPVErythrocytosis #Erythrocytosis #Hematology @ash.edu.hematology.org @bsochaem.bsky.social @vjhemonc.bsky.social @rarediseasectn.bsky.social @rarediseasesint.bsky.social